Radiation Therapy (External Beam Radiation Therapy - EBRT)
Treatment for Bladder Cancer
Typical Dosage: 60-66 Gy in 30-33 fractions
Effectiveness
65%
Safety Score
30%
Clinical Trials
19
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
60-66 Gy in 30-33 fractions
Time to Effect
3-6 months
Treatment Duration
6-7 weeks
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$40,000
Monitoring:$7,500
Side Effect Mgmt:$5,000
Total Annual:$52,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$40,000/QALY
QALYs Gained
2.5
Outcome-Based Costs
Cost per Responder
$70,000
Cost per Remission
$116,666.67
Comparison vs Radical Cystectomy
Cost Difference
$-50,000/year
Less expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Radiation Therapy (External Beam Radiation Therapy - EBRT) Outcomes
for Bladder Cancer
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+75%
Remission Rate
+45%
Common Side Effects
Acute radiation cystitis
+65%
Acute radiation proctitis
+40%
Skin irritation/dermatitis
+70%
Fatigue
+60%
Chronic bladder/bowel dysfunction
+15%
Sources:
Active Clinical Trials
9 active trials recruiting for Radiation Therapy (External Beam Radiation Therapy - EBRT) in Bladder Cancer
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer
NCT03601455ACTIVE NOT RECRUITINGPHASE2
13 participants
INTERVENTIONAL
Los Angeles, United States
Started: Oct 26, 2018
Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer
NCT04186013ACTIVE NOT RECRUITINGPHASE2
39 participants
INTERVENTIONAL
Manresa, Spain +9 more
Started: Sep 18, 2019
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
NCT02621151ACTIVE NOT RECRUITINGPHASE2
60 participants
INTERVENTIONAL
Chicago, United States +4 more
Started: Aug 11, 2016
Image-Guided Radiation Therapy for Bladder-Cancer Patients Undergoing Radiotherapy and Concurrent Gemcitabine Chemotherapy
NCT01104350ACTIVE NOT RECRUITINGPHASE1
19 participants
INTERVENTIONAL
Basking Ridge, United States +4 more
Started: Apr 1, 2010
Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach
NCT05295992RECRUITINGNA
110 participants
INTERVENTIONAL
Herlev, Denmark
Started: Mar 15, 2022
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
NCT03317158RECRUITINGPHASE1, PHASE2
55 participants
INTERVENTIONAL
Phoenix, United States +11 more
Started: Nov 21, 2017
Bladder and Bone Effects of Pelvic Radiation Therapy in Childhood Cancer Survivors
NCT05818462RECRUITING
60 participants
OBSERVATIONAL
Aurora, United States
Started: Jul 11, 2023
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
NCT07061964RECRUITINGPHASE2
111 participants
INTERVENTIONAL
Birmingham, United States +85 more
Started: Nov 25, 2025
A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.
NCT07268339NOT YET RECRUITINGPHASE3
328 participants
INTERVENTIONAL
Manchester, United Kingdom
Started: Dec 1, 2025
Completed Clinical Trials
4 completed trials for Radiation Therapy (External Beam Radiation Therapy - EBRT) in Bladder Cancer
Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.
NCT00330499COMPLETEDPHASE3
67 participants
INTERVENTIONAL
Liverpool, Australia +21 more
Started: Oct 1, 2002
Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach
NCT03702179COMPLETEDPHASE2
32 participants
INTERVENTIONAL
Badalona, Spain +6 more
Started: Nov 19, 2018
Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer
NCT01170299COMPLETEDNA
177 participants
INTERVENTIONAL
London, United Kingdom
Started: Oct 1, 2009
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
NCT04430842COMPLETEDPHASE1
15 participants
INTERVENTIONAL
Kogarah, Australia +1 more
Started: Jul 20, 2020